FDA declines to approve Bristol-Myers hepatitis drug

(Reuters) - Bristol-Myers Squibb Co on Wednesday said U.S. regulators had declined to approve use of its experimental daclatasvir drug for hepatitis C, in combination with other antiviral drugs. Bristol-Myers said it had initially sought permission from the U.S. Food and Drug Administration to market the drug, a so-called NS5A inhibitor, in combination with another experimental company medicine called asunaprevir that Bristol-Myers abandoned in October because of competition from more potent rival drugs. (Reporting by Ransdell Pierson)



via Health News Headlines - Yahoo News http://ift.tt/1zv5uCM